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bstract
Type-A procyanidine polyphenols (TAPP) are reported to have immunomodulatory and anti-inflammatory potential in  vitro. The objective of
resent work is to evaluate potential of TAPP extracted from Cinnamon (Cinnamomum  zeylanicum) bark in animal models of inflammation and
heumatoid arthritis in rats. Carrageenan-induced rat paw edema (CPE) and adjuvant induced established arthritis (AIA), in rats were used as
he experimental models for inflammation and arthritis respectively. Analgesic activity was evaluated in Randall–Selitto assay in AIA rats. TAPP
howed significant anti-inflammatory effect at dose of 4, 8 and 25 mg/kg, p.o. but not at 2 mg/kg, p.o. dose in CPE model. The dose of 8 mg/kg, p.o.
as selected for the evaluation of anti-arthritic activity in AIA model. TAPP (8 mg/kg, p.o., daily from day-12 to day-21) treatment in established
rthritic rats showed significant reversal of changes induced in AIA with respect to body weight drop (cachexia), ankle diameter, arthritic score,
erum C-reactive protein (CRP) levels. Moreover, TAPP was found to be non-ulcerogenic as compared to AIA control rats. However, TAPP did not
how analgesic effect on AIA-induced pain as seen in Randall–Selitto assay. In conclusion, TAPP showed disease-modifying potential in animal
odels of inflammation and arthritis in rats.
 2013 Beijing Academy of Food Sciences. Production and hosting by Elsevier B.V. All rights reserved.
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.  Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory,
utoimmune disease, affecting freely movable joints, such as
and, knee and shoulder joints. The symptoms of active RA
nclude pain, swelling, morning stiffness, warmth, redness,
Abbreviations: TAPP, type-A procyanidine polyphenols; CPE, carrageenan-
nduced rat paw edema; AIA, adjuvant induced established arthritis; CRP,
-reactive protein; FCA, Freund’s complete adjuvant; DTH, delayed-type
ypersensitivity; LPS, lipopolysaccharide; RA, rheumatoid arthritis; NSAID,
on-steroidal anti-inflammatory drug; DMARD, disease-modifying anti-
heumatic drugs.
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aheumatoid arthritis
nd limits in the functions of the joints. The systemic ram-
fications of the disease, apart from morbidity and mortality,
nclude cardiopathy, nephropathy, vasculopathy and pulmonary
nd cutaneous disorders [1]. Although the cause of rheumatoid
rthritis is unknown, autoimmunity plays a pivotal role in both its
hronicity and progression, and RA is considered as a systemic
utoimmune disease.
Existing treatment therapies for RA usually focused on
nti-inflammatory activity. They help to check the process of
nflammation and thus may also help in the repair process. Med-
cations like non-steroidal anti-inflammatory drugs (NSAIDs),
orticosteroids and analgesics are used to suppress the symptoms
hile disease-modifying anti-rheumatic drugs (DMARDs) and
iological response modifiers often required to inhibit or halt
he underlying immune process and prevent long-term damage.
Although NSAIDs, DMARDs and corticosteroids appear to
e highly efficient drugs in the treatment of rheumatoid arthritis,
hey may cause side effects that can range in severity from mild
o serious. The major adverse drug reactions (ADRs) associ-
ted with NSAIDs are gastrointestinal (ulceration or bleeding),
nd cardiovascular (myocardial infraction) with effects on other
ystems. Despite of its wide clinical use, gastrointestinal (GI)
oxicity, upper GI adverse events such as perforation, ulceration
nd bleeding in about 20% of patients taking long-term NSAIDs
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s a major clinical limitation. Besides, some NSAIDs were with-
rawn from the market because of the risk of heart attacks and
troke in some and some others had “Black box” warning in the
ackage insert addressing risk of suffering from heart attacks
nd/or stroke [2]. On the other hand, other therapies against
rthritis such as DMARDs and biological agents had a risk of
mmunosuppression and serious infection respectively on long-
erm usage. Therefore, search for safer drugs for management
f rheumatoid arthritis for chronic use is still going on.
Cinnamon (Cinnamomum  zeylanicum  Syn C.  verum, family:
auraceae) bark is one of the oldest herbal medicines mentioned
n many traditional text for inflammatory [3], and pain related
o disorders such as enteralgia (acute intestinal pain), bronchi-
is, and rheumatism [4]. It is native to Sri Lanka, Mayanmar
Burma) and the southern coastal strip of India. In Chinese
raditional medicine, cinnamon is indicated as an analgesic
nd antipyretic agent against cold, fever, headache, myalgia
mascular pain), arthralgia (arthritic pain) and amenorrhea (fail-
re of menstruation). In Indian traditional literature including
yurveda, many other valuable actions are attributed to cinna-
on bark [5].
Many scientific pharmacological investigations are also
eported on anti-inflammatory potential of the bark of many
pecies of cinnamon [4,6,7]. The anti-inflammatory action of
he Japanese species Cinnamomum  seiboldii  [8] and Cinnamomi
ortex [9] has been attributed to a series of tannins. The antinoci-
eptive activity (analgesic) [10] and antipyretic (fever reducing)
ctivity C.  verum  bark [8] were also been reported.
An interesting factor about cinnamon is that it can act both
s an immunostimulant and a suppressant depending on species
nd doses [11]. Another important activity is the immunomod-
latory effects exerted by cinnamon bark. In  vitro  inhibitory
ctivity against complement formation has been documented for
innamon cortex and oil [11]. The extract of cinnamon bark is
eported to have anti-complementary [12] and immunosuppress-
ve [13] activity. Cinnamon bark’s potential for inflammation,
ain and immune system makes it a good candidate as an anti-
rthritic agent [14]. However, the component (s) responsible for
hese activities is not known. Cinnamon bark polyphenol extract
ad been shown anti-inflammatory properties in  vitro  and ther-
peutic potential for prevention and treatment of inflammation
elated diseases [15,16].
The oligomeric end products of the flavonoid biosynthetic
athway in Cinnamon are procyanidins whose building blocks
re (+)-catechin and (−)-epicatechin [17]. Proanthocyani-
in (procyanidin, oligomeric proanthocyanidins, leukocyanidin,
eucoanthocyanin and condensed tannins) is a class of flavanols,
re now identified and recognized for their favorable effects in
uman beings.
The anti-inflammatory action has been attributed to polyphe-
olic components such as tannins [8] and procyanidins [17] from
 variety of natural products. Based on the linkage between
he successive monomeric units, procyanidins are classified
s Types A, B or C procyanidine polyphenols. Type-A pro-
yanidine polyphenols (TAPP) from cinnamon bark has been
eported to exhibit activities against microorganisms [18], sug-
esting a potential role of TAPP in regulating immune function
o
[
(
tman Wellness 2 (2013) 59–67
ith unknown mechanism. Further, TAPP has been shown
nti-inflammatory effects in cell culture studies in  vitro  [16].
ecently, we have demonstrated ameliorative effects of TAPP
rom cinnamon bark in animal model of allergic asthma [19].
owever, TAPP has not yet been evaluated in  vivo  using animal
odels of rheumatoid arthritis (RA). The objective of present
ork is to evaluate efficacy and safety of TAPP isolated from C.
eylanicum  in animal model of acute inflammation and RA in
ats.
.  Materials  and  methods
.1.  Materials
Wistar rats of either sex (130–200 g) were obtained from
ational Toxicology Center, Pune, India. The rats were divided
nto groups having six rats per group and housed in polypro-
ylene cages at a temperature of (24 ±  1) ◦C with 12 h:12 h
ark–light cycle, with free access to standard pellet feed (Chakan
il Mill, India) and filtered water. All experiments were carried
ut between 08:00 am and 17:00 pm in a quiet laboratory. The
esearch protocol was approved (No. CPCSEA/48/08) by Insti-
utional Animal Ethics Committee (IAEC) and as per Indian
orms laid down by Committee for the Purpose of Control
nd Supervision of Experimental Animals (CPCSEA), New
elhi.
The test compound, TAPP was provided by Indus Biotech Pri-
ate Limited, Pune, India, after characterization as per reported
rocedures [19–21]. The TAPP is a standardized extract of C.
eylanicum  bark with pentameric type-A procyanidine flavonoid
s a marker compound (75.9% purity) with presence of trimer
nd tetramer. The solutions of TAPP was freshly prepared daily
y dissolving in mixture of propylene glycol and distilled water
n ratio of 30:70 to make solution of 1 mg/mL concentration and
dministered orally.
.2.  Anti-inﬂammatory  activity  against  CPE  model
Anti-inflammatory activity was evaluated on the basis of the
nhibition of the CPE [22,23]. Each rat in the experimental group
six rats each) was treated orally with 2, 4, 8 and 25 mg/kg
ody weight, 1 h before an edematogenic agent, carrageenan
Sigma–Aldrich, USA) injection. Carrageenan (0.1 mL of a 1%
uspension prepared in 0.9% NaCl) was injected into the sub-
lanter aponeurosis of the left hind paw of rats with 26-gauge
eedle. One group of rats was treated orally with 5 mg/kg body
eight of diclofenac sodium as a standard drug. Separate vehicle
ontrol group was also maintained. Paw volume was measured
mmediately after carrageenan injection (time 0) and at 1, 3,
 and 24 h using a plethysmometer (Model 7150, Ugo Basile,
taly). Mean difference in paw volume (mL) was calculatedf paw volume at 3 h were calculated with a reported formula
24] from mean difference in mean paw volume (mL) in treated
Vt) and control (Vc) group according to the equation: % inhibi-
ion = (Vt/Vc) × 100.
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.3.  Effect  on  adjuvant-induced  established  polyarthritis
AIA)
Arthritis was induced according to method described ear-
ier [25] and as modified for therapeutic schedule. AIA was
nduced in 6–8 week-old rats by a single intradermal injection
f 0.1 mL Freund’s complete adjuvant (FCA) into the footpad
f the right hind paw. FCA contains 0.6 mg heat-inactivated
ycobacterium  tuberculosis  H37Ra (Difco Laboratory, Detroit,
I, USA) emulsified in a sterile mixture of paraffin oil, saline
nd Tween-80. Arthritis was allowed to develop for next 12 d.
n day 12, animals were randomly assigned to one of the follow-
ng treatment groups: arthritic untreated controls (AIA controls),
rthritic rats treated with diclofenac sodium (1 mg/(kg·d)) and
rthritic rats treated TAPP (8 mg/(kg·d)). These groups of rats
ere orally treated once daily with vehicle (distilled water),
iclofenac sodium or TAPP respectively from the day-12 to
ay-21 by oral feeding needle. Body weight and pain latency
f inflamed paw, ankle diameter, arthritis score and serum C-
eactive protein (CRP) levels were measured on day-0 (baseline,
efore arthritis induction), day-12 and day-21 of the study. Total
ody weight was recorded every 3rd day from day 3 to day 21.
he increase in body weight was calculated relative to that at
ay 0 allowing monitoring of the decrease in body weight gain
ssociated with arthritis [26]. The diameter of the inflamed paw
oint (ankle) was measured by Vernier Caliper [27]. The joint
as compressed by pressing the gauge till pain was elicited as
ndicated by squeaking or leg withdrawal. The distance moved
y the screw gauge was recorded.
Swelling in hind paws were recorded by using a plethys-
ometer (UGO Basile Italy.) on day-0, day-12 and day-21
fter the FCA injection [28]. The rats were scored regularly
or arthritis severity score based on swelling of paws [29] by
wo investigators who were blind to the treatment. Each paw
as graded according to the severity and extent of erythema
nd swelling of periarticular soft tissues in the enlargement and
istortion of the joints. The arthritis scores were ranged from 0
no sign) to 4 (severe lesions), yielding a maximum score of 16
er animal. Pain stimulus was measured by the method reported
arlier [30].
.4.  Biochemical  estimations
The measurement of C-reactive protein was carried out
ccording to earlier reported method [31]. Blood samples were
ithdrawn retro orbital puncture under light anesthesia on day-
, day-12 and day-21 of the study. The serum was separated
nd samples were analyzed for CRP by commercially avail-
ble enzyme-linked immunesorbent assay (ELISA) kit for CRP
R&D system, USA) according to the manufacturers’ recom-
endations.
.5.  Randall–Selitto  assayPain latencies were measured using Randall–Selitto
nalgesymeter (Ugo basile Model 7200) during AIA model on
ay 0 (induction of AIA), day-12 (start of treatments) and day-21
s
N
r
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end of the study). Pain latencies were measured by the threshold
timulus for reaction (escape or paw withdrawal) using a weight
f 500 g applied to the pads of hind paws.
.6.  Serum  turbidity  measurements
On day-21, rats were sacrificed by cervical dislocation
fter administration of light ether anesthesia. Blood was with-
rawn by cardiac puncture. The serum turbidity of sacrificed
rthritic rats on day-21 was measured by earlier reported
ethod [32]. To 0.1 mL of nonhaemolyzed serum, 2.9 mL
f 0.067 mol/L sorenson phosphate buffer composition: 2 mL,
.067 mol/L monopotassium phosphate + 98 mL, 0.067 mol/L
isodium phosphate in saline (pH 5.2) was added and gently
gitated. The mixture was allowed to stabilize at room tempera-
ure for 15 min before being incubated in a constant temperature
ater bath at 69 ◦C for 30 min. The samples were cooled in an
ce bath and absorbance was read as serum turbidity in a spec-
rophotometer (Shimadzu, Japan) at the wavelength of 645 nm.
.7.  Microscopic  study
Microscopic evaluation was done by analyzing the histology
f stomach sections [60]. Freshly excised stomach of one ani-
al from each group was washed with saline and preserved
n 10% formaldehyde solution for histopathological studies.
hey were processed for 12 h using isopropyl alcohol, xylene
nd paraffin. Then sections of stomach were cut (5 m thick-
ess) with microtome. Sections were deparaffination and stained
sing hematoxylin and eosin (H&E) stain. The sections were
hen observed and photomicrographs were taken for histology
ssessment.
.8.  Statistical  analysis
Data were obtained for each set of parameters separately
or experiments namely CPE and AIA model and expressed as
eans ±  SEM. Data were analyzed by two-way repeated meas-
res ANOVA followed by Bonferroni posttests separately for
ach parameter. Data for serum turbidity measurement were ana-
yzed by one-way ANOVA followed by Dunnett’s test. Level of
ignificance was set at P  < 0.05. All statistical tests were carried
ut using Prism 5.0 (Graph Pad, San Diego CA, USA) statistical
oftware.
.  Results
.1.  Effect  of TAPP  in CPE  model
Subplanter injection of carrageenan produced significant
mount of edema (increase in paw volume) in all the groups of
nimals. Increase of paw volume (edema) was observed within
n hour (paw volume increases by 0.69 mL). This edema was
ustained up to 6 h (increase by 1.65 mL) (Table 1). The standard
SAID, diclofenac sodium (5 mg/kg, p.o.) caused significant
eduction in edema (anti-inflammatory effect) compared with
ehicle treated rats (P  < 0.001) at 1 h of treatment until 6 h.
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Table 1
Effect of various doses of TAPP against carrageenan-induced rat paw edema (CPE) in rats.
Treatment (dose in mg/kg, oral) Difference of paw volume (mL) % Inhibition of edema at 3 h
1 h 3 h 6 h 24 h
Vehicle control 0.69 ± 0.02 1.42 ± 0.07 1.65 ± 0.11 0.89 ± 0.14 –
Diclofenac sodium (5) 0.14 ± 0.03*** 0.17 ± 0.05*** 0.24 ± 0.11*** 0.17 ± 0.02*** 88.02
TAPP (2) 0.58 ± 0.09 1.31 ± 0.07 1.55 ± 0.09 0.74 ± 0.12 7.74
TAPP (4) 0.86 ± 0.04 1.03 ± 0.04* 1.01 ± 0.13*** 0.01 ± 0.02*** 27.47
TAPP (8) 0.67 ± 0.03 0.92 ± 0.04*** 1.04 ± 0.13*** 0.46 ± 0.07*** 35.21
TAPP (25) 0.32 ± 0.08* 0.52 ± 0.13*** 0.76 ± 0.18*** 0.28 ± 0.06*** 63.38
Data are represented as Mean change paw volume (mL) ± SEM, n = 6. The difference of paw volume for each rat was calculated with respect to baseline readings
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nnd was analyzed by Two-way repeated measures ANLOVA followed by Bon
epresented as: * P < 0.05; **P  < 0.01; *** P < 0.001.
ral treatment of the test compound, TAPP showed significant
P < 0.001) anti-inflammatory effects at 4 mg/kg, 8 and 25 mg/kg
ose levels. However, at 2 mg/kg, p.o. dose, TAPP did not show
nti-inflammatory effect. The onset of effect for TAPP was at
 h, 3 and 1 h for dose levels of 4, 8 and 25 mg/kg respectively.
t 3 h, TAPP (8 and 25 mg/kg) showed 27.47%, 35.21% and
3.38% inhibition of edema respectively compared to 88.02%
nhibition showed by diclofenac sodium (5 mg/kg) treatment.
.2.  Effect  of  TAPP  on  AIA  in  rats
.2.1.  Effect  on  body  weight  reduction  (Cachexia)  in  AIA
ats
Single intradermal injection of FCA into the footpad of the
at hind paw brought significant (P  < 0.001) reduction in body
eight (cachexia) in all the rats on day-12 of the study. In
IA control rats treated with vehicle, the weights were further
educed (from 202.50 g to 184.67 g) during day-12 to day-21
Table 2). In the same period (day-12 to day-21), subacute
ral administration of diclofenac sodium (1 mg/kg) halted the
achaxia of AIA (P  < 0.01). The body weights were increased
rom 197.17 g to 206.5 g after diclofenac sodium treatment. Sim-
lar cachexia reversal effect was found in rats after subacute
ral treatment (day-12 to day-21) with TAPP in AIA. TAPP
8 mg/kg) showed significant (P  < 0.05) increase in body weight
rom 196.50 g to 208.33 g.
n
i
o
able 2
ffect of TAPP (8 mg/kg, p.o.) on body weight, ankle diameter and serum C-reactiv
ats.
arameter Day of study AIA co
ody weight (g) 0 215.67 
12 202.50 
21 184.67 
nkle diameter (mm) 0 5.82 
12 7.71 
21 7.88 
erum C-reactive protein (CRP)
mg/mL)
0 7.33 
12 9.38 
21 8.77 
ata are represented as mean ± SEM, n = 6. Data for each parameter were separate
osttests. Compared to day-12 for respective treatment group, significance represente
espective treatment group, significance represented as: # P < 0.05; ## P < 0.01; ### P 
s - not significant as compared to day-12 for respective treatment group.i posttests. Compared to vehicle control at respective time point, significance
.2.2.  Effect  on  ankle  diameter  in  AIA  rats
Ankle diameter of inflamed paw in AIA rats were found to
ncrease significantly (P  < 0.001) in all rats on day-12 compared
ith day-0 of the study (Table 2). On day-21 of the study, mean
nkle diameters of rats with AIA rats treated with vehicle did not
ave significant change (Table 2) compared with day-12. On the
ther hand, significant (P  < 0.001) reduction in ankle diameter
f AIA rats was found on day-21 compared with day-12 with
reatment of diclofenac sodium (from 7.64 mm to 6.82 mm) and
APP (from 8.30 mm to 7.30 mm) (Table 2).
.2.3. Effect  on  serum  C-reactive  protein  levels  in  AIA  in
ats
The C-reactive protein (CRP) level in serum samples were
ound to increase on day-12 of the study in all rats (Table 2).
he increase in serum CRP levels was sustained on day-21 in
IA control rats. On day-21, significant reduction of CRP levels
ere found in serum samples of AIA rats treated with diclofenac
odium (from 10.24 mg/mL to 7.47 mg/mL) and TAPP (from
0.28 mg/mL to 8.15 mg/mL) (Table 2).
.2.4. Effect  on  total  arthritis  score  in  AIA  rats
The total arthritis score in inflamed paw was increased sig-
ificantly in 12 d after induction of arthritis (Table 3). Further,
ncrease in total arthritis score was found in AIA control rats
n day-21 of the study (Table 3). However, significant reduction
e protein (CRP) levels against FCA-induced established polyarthritis (AIA) in
ntrol Diclofenac sodium (1) TAPP (8)
± 2.04 213.50 ± 3.41 218.17 ± 4.16
± 1.48### 197.17 ± 1.01### 196.50 ± 1.77###
± 0.95*** 206.50 ± 1.57** 208.33 ± 2.11*
± 0.23 5.70 ± 0.30 5.81 ± 0.17
± 0.10### 7.64 ± 0.38### 8.30 ± 0.15###
± 0.07ns 6.82 ± 0.38*** 7.30 ± 0.12***
± 0.03 7.01 ± 0.09 7.39 ± 0.53
± 0.18# 10.24 ± 0.14## 10.28 ± 0.43##
± 0.04ns 7.47 ± 0.24* 8.15 ± 0.05**
ly analyzed by two-way repeated measures ANOVA followed by Bonferroni
d as: * P < 0.05; ** P < 0.01; *** P < 0.001. Compared with day-0 reading for
< < 0.001.
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Table 3
Effect of TAPP (8 mg/kg, p.o.) on total arthritis score and pain latency against FCA-induced established polyarthritis (AIA) in rats.
Parameter Day of study AIA control Diclofenac sodium (1) TAPP (8)
Total arthritis score 0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
12 6.67 ± 0.33# 6.83 ± 0.17# 6.17 ± 0.17#
21 8.50 ± 0.22* 2.67 ± 0.33* 2.00 ± 0.26*
Pain latency (s) in Randall–Sellito
assay
0 16.83 ± 0.70 18.08 ± 0.70 19.50 ± 0.52
12 3.83 ± 0.21# 4.08 ± 0.30# 5.42 ± 0.79#
21 2.25 ± 0.50ns 3.58 ± 0.45ns 6.92 ± 0.61ns
Data are represented as mean ± SEM, n = 6. Data of each parameter were analyzed separately by two-way non-parametric ANOVA followed by Bonferroni “t” test.
Compared to day-12 for respective treatment group, significance represented as: * P < 0.05. Compared with day-0 reading for respective treatment group, significance
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s - not significant as compared to day-12 for respective treatment group.
n arthritis score of AIA was brought by subacute treatment of
iclofenac sodium (from 6.83 to 2.67) or TAPP (from 6.17 to
.00) as observed on day-21 of the study (Table 3).
.2.5. Effect  on  pain  latency  of  inﬂamed  paw  (Randall  and
elitto  assay)  in  AIA  rats
The pain latency tested in Randall and Selitto analgesiometer
as found to decrease significantly in all rats. The reduction
as found to be as high as 19.50 to as low as 3.83 (Table 3).
he pain latencies were found to further decrease to 2.25 sec in
IA control rats. Subacute administration of diclofenac sodium
r TAPP in AIA rats did not change pain latencies on day-21
ompared to day-12 (Table 2).
.2.6. Effect  on  change  in  serum  turbidity  in  AIA  rats
Absorbance of various serum samples on day-21 in AIA
ontrol rats are presented in Fig. 1. The serum samples of non-
rthritic rats showed absorbance of 0.3493 whereas AIA control
ats (vehicle treated) reduced absorbance to 0.1295 (P  < 0.001).
he subacute treatment with diclofenac sodium in AIA con-rol rats from day-12 to day-21 did not cause any change in
bsorbance compared with serum samples of AIA control rats.
he serum samples of AIA rats treated with TAPP showed mild
ig. 1. Effect of TAPP (8 mg/kg) on serum turbidity of FCA-induced arthritic
ats on day-21. Data are represented as absorbance at 645 nm ± SEM and was
nalyzed by one-way ANOVA followed by Dunnett’s “t” test. Absorbance of
erum samples was measured on day-21 of the study. n = 6. ###P < 0.001 as
ompared with non-arthritic rats; *P < 0.05 as compared with arthritic control
roup.
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mncrease (from 0.1295 to 0.1621, P < 0.05) in absorbance com-
ared with AIA control (Fig. 1).
.2.7. Histology  of  gastric  mucosa  in  AIA  rats
Gastric mucosal superficial layer of stomach samples of rats
emoved from normal non-arthritic (Fig. 2A) rats were found
o be smooth. The mucosal epithelial layer of stomach sections
f AIA control rats treated with vehicle (Fig. 2B) or TAPP at
ral dose of 8 mg/kg (Fig. 2D) were also found to be normal and
mooth with mild capillary dilation. However, superficial layer
f gastric mucosa of AIA rat treated with subacute treatment of
iclofenac sodium (1 mg/kg, p.o.) had multiple areas of erosions
nd hemorrhage (Fig. 2C).
.  Discussion
The cinnamon bark polyphenol extract is water-soluble and
an be standardized to type-A proanthocyanidins [33]. In the
resent study, we are reporting anti-inflammatory and anti-
rthritic potential of type-A proanthocyanidins from cinnamon
ark, TAPP, in animal models.
The recognition of different mediators for different phases
f CPE has important implications for interpreting the anti-
nflammatory effect of the drugs. The development of such
dema in the rat paw is a biphasic event. The initial phase of
he edema has been attributed to the release of histamine and
erotonin which is then maintained during the plateau phase
ecause of kinin-like substances [34]. Further, involvement of
istamine and serotonin with other mediators in the pathogenesis
f rheumatoid arthritis was also reported by many researchers
35–37]. Effectiveness of the test compounds in the 1st hour
fter carrageenan injection is indicative of their antihistaminic
nd/or anti-serotonin action. The 2nd accelerating phase of car-
ageenan edema is attributed to release of prostaglandins [38].
ur test compound, TAPP was not effective in the 1st hour of
reatment but was found effective in the 2nd phase at 8 mg/kg
nd higher dose (observed at 3 h) thus suggesting prostaglandins
nhibition effect of TAPP (Table 1). However, possibility of other
echanism such as inhibition of leukocyte emigration by TAPP
annot be ruled out.
The ability of anti-inflammatory test compounds to offer
enefits in clinical management of rheumatic diseases and so
odification of arthritic syndromes in laboratory animals is an
64 S. Vetal et al. / Food Science and Human Wellness 2 (2013) 59–67
Fig. 2. Photomicrograph of stomach on day-21 of the study. The figure shows sections of stomach of (A) normal rats, (B) AIA control rats with treatment from
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pay-12 to day-21 of vehicle (distilled water), (C) diclofenac sodium (1 mg/kg, p.
f the mucosa and (D) TAPP (8 mg/kg, p.o.) treated arthritic rats; M. mucosa, M
t 40×.
mportant criterion in anti-inflammatory screening procedure.
n 1963, AIA in rats was used as primary animal model for RA
sing intradermal administration of Freund adjuvant in oil emul-
ion [39]. AIA is a rather aggressive and monophasic form of
rthritis. Usually, the AIA is severe and finally leads to complete
nkylosis and permanent joint deformations similar to progres-
ive symptoms of RA patients. AIA has been used extensively as
n experimental model for studying immune-inflammatory pro-
esses of arthritic diseases in humans, in particular RA, as well as
or screening and testing novel anti-arthritic agents [40]. There-
ore, we tested TAPP against established polyarthritis model of
IA rats using therapeutic schedule of treatment [25,41]. We
nduced AIA in rats, allowed it to develop for 12 d and evalu-
ted effects of TAPP on day-21 of the study. The progression
f arthritis was confirmed in our study by scoring total arthritis
esions. The diseases progressed till day-12 and then became
uiescent. TAPP halted the progression which was evident by
ignificant decrease shown in the total arthritic score (Table 3).
The inflammation associated with AIA is mainly depend-
nt on prostaglandin E2 (PGE2) generated by cyclooxygenases
COXs) [40,42]. Besides, the role of cytokines like TNF-  and
L-1 has also been implicated in this model [43]. TAPP treatment
w
m
sated arthritic rats shows erosion (arrow) with hemorrhage at the superficial part
uscularis mucosa, and L. lumen. Stained with hematoxylin and eosin (H&E)
o AIA rats reduced ankle diameters of arthritic paw. There-
ore, the anti-inflammatory action of TAPP may be mediated
y prostaglandin and/or cytokine inhibition. These results are
lso in line with reports that anti-inflammatory action of cinna-
on bark has been attributed to polyphenolic component such
s tannins [8] and procyanidines [17]. The inhibition of lipid
eroxidation, capillary permeability and fragility, and enzymes
uch as phospholipase A2, cyclooxygenase, and lipoxygenase
ere reported as alleged mechanism for cinnamon tannins and
olyphenols [8,17].
Analgesia is an important ancillary property of all anti-
nflammatory agents. Most of the anti-inflammatory drugs
ncreased pain threshold in various animal models [44]. This
s natural because many endogenous chemical mediators of
nflammation play a part in generating pain impulses (for exam-
le, histamine, serotonin and prostaglandins) and some other
ediators such as bradykinin and cytokines, are involved in
rolongation of the sensation of the pain [45].
RA is an inflammatory condition of the joint that is associatedith hyperalgesia and functional impairment [46]. Joint inflam-
ation induced by AIA is associated with hyperalgesia and
light compression of the joint which caused leg withdrawal and
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queaking. The hyperalgesia associated with arthritis has been
eported to involve prostaglandin synthesis [47]. Increased levels
f substance P, calcitonin gene-related peptide and up-regulation
f neurokinin-1 receptor in the dorsal horn of the rat spinal
ord have been reported to play an important role in modulat-
ng both inflammation and hyperalgesia in the FCA model [48].
owever, in the present study, TAPP did not prevent reduction
ain latency in Randall–Selitto assay. Therefore, nociception-
elated mediators (substance-P, calcitonin gene-related peptide
nd neurokinin-1) are not involved in mechanism of action of
APP. This also pointed toward the possibility of disease mod-
fication as possible mechanism of action of TAPP against RA.
AIA has been generally believed to be the result of a delayed-
ype hypersensitivity (DTH) response to a disseminated antigen
robably derived from the injected bacterial cell wall [49]. AIA
n rats is a useful model of inflammatory cachexia that mim-
cs the human pathophysiology in many important ways [50].
IA induces inflammation as primary lesion which reached to
eak after 3–5 d with secondary lesions occur after a delay of
bout 11–12 d. Secondary reactions in AIA are characterized
y immune responses, inflammation and decrease of weight
cachexia). In our study, the test compound, TAPP significantly
rotected rats from cachexia because of arthritis induction.
In the past, many plant-derived procyanidines reported to
ave cytokine inhibitory effect in  vitro  [51,52]. Similar effects
ere also attributed to Cinnamon bark extract and polyphenols
16,53]. In  vitro  pre-challenge with cinnamon extract is reported
o suppress lipopolysaccharide (LPS)-induced cytokines expres-
ion [54]. Recently, immune regulatory action of TAPP in mouse
T3-L1 adipocytes is attributed to TTP (tristetraprolin) [55].
esides, TAPP is capable of affecting immune responses by
egulating anti-inflammatory mediators as well as the TTP gene
xpression in macrophages [16]. Taken together, cytokine inhi-
ition emerges as a probable mechanism of TAPP responsible
or cachexia reducing effects in AIA-induced established pol-
arthritis in rats. This probability is also supported by our result
hat TAPP reduces serum C-reactive protein (CRP) levels of
ats on day-21 compared to day-12 levels (Table 2) whereas
IA control rats showed sustained increase in CRP till day-21
Table 2).
CRP is an acute-phase protein and has been identified as
n important biomarker for various inflammatory, degenerative,
nd neoplastic diseases [56,57]. Elevated levels of CRP have
een found in the blood during almost all diseases associated
ith active inflammation or tissue destruction, particularly in
A patients [57,58]. Sustained increase in serum CRP levels
uggests a lasting production and stimulation of acute-phase
roteins during disease progression.
In our study, serum turbidity (showed by absorbance of
erum samples) of AIA control rats was found to be signifi-
antly reduced compared with normal rats (Fig. 1). Treatment
rom day-12 to day-21 with TAPP but not diclofenac sodium
an NSAID) prevented AIA-induced fall in turbidity (Fig. 1).
he decrease in serum turbidity in AIA control rats, is known
o be caused by denatured products and was shown to be cor-
elated with severity [59] and immune response seen in AIA
60]. Further, increased levels of serum lysozyme levels wereman Wellness 2 (2013) 59–67 65
eported to be strongly correlated with decreases in serum tur-
idity in AIA [59]. Therapeutically useful anti-inflammatory
rugs were shown to reverse this decrease in serum turbidity
32]. Taken together, our results strongly pointed to disease-
odifying properties of TAPP and its potential to slow down
he RA progression.
One of the most prominent and serious side effects of
SAIDs is occurrence of gastrointestinal damage (ulcerogenic-
ty). Hence, it was necessary to test our compounds for their
lcerogenicity potential. In the present study, subacute treat-
ent of TAPP (8 mg/kg, p.o.) did not cause severe ulcerogenicity
s compared to significant ulcerogenicity shown by diclofenac
odium (1 mg/kg, p.o.) in established AIA in rats.
The absence of the analgesic and the ulcerogenicity poten-
ial with reduction in serum CRP levels in AIA rats qualifies
APP as a disease-modifying anti-rheumatic drug (DMARD).
MARDs suppress the rheumatoid process and bring about a
emission, but do not have nonspecific anti-inflammatory or
nalgesic action. TAPP offer added advantage of moderate anti-
nflammatory effects at daily dose of 8 mg/kg, p.o. in arthritic
ats. The DMARD effects shown by TAPP can also be substanti-
ted by earlier reports on cinnamon bark extracts. For example,
innamon bark was shown to inhibit gastric secretions [11] and
radicate H.  pylori  (a bacteria known to exacerbate gastric acid-
ty and ulcers) [61,62]. TAPP is also expected to be protective on
he cardiovascular system as cinnamon polyphenols especially
APP by virtue of its antioxidant activity [63,64].
.  Conclusion
In conclusion, TAPP, type-A procyanidine polyphenols iso-
ated from the bark of C.  zeylanicum  showed anti-inflammory
nd anti-arthritic effects in animal models without ulcerogenic-
ty potential. Lack of analgesic activity in present study and
eports of immunomodulatory potential suggested TAPP as
otential DMARD. Further studies are required to explain the
echanism of action of TAPP toward autoimmune and inflam-
atory disease processes.
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